Background: Canine anti-mouse antibodies are a potential source of immunoassay interference, but erroneous immunoassay results are not always easily identifiable.
| INTRODUC TI ON
Since the invention of the radioimmunoassay in the 1950s, immunoassays have become the standard methods for the detection of many clinically important proteins and peptides. Without immunoassays, the diagnosing many medical conditions and being able to monitor these medical conditions at follow-up visits would be seriously affected. However, despite several years of advancements in immunoassay development, there are still some limitations. One particularly striking flaw inherent to immunoassays is the risk of interference from endogenous antibodies in patient serum and plasma.
By emulating the actions of the analyte of interest, these antibodies can cause false-positive results. Immunoassay manufacturers routinely include warnings about interfering "heterophilic antibodies" or "HAMAs" (human anti-mouse antibodies) in package inserts. In practice, this information will usually not reach the veterinary clinician, or could simply be dismissed, perhaps because such antibodies are perceived to be very rare or absent in animals. We have developed a species-independent assay detecting endogenous anti-mouse antibodies and estimated a prevalence of 9% in dogs and 5% in cats. 1 The suspicion of immunoassay interference could be raised when test results are discordant with the clinical presentation of the patient. An increase marker measurement for no apparent reason could also indicate interference. If the measurement has a high impact on the course of treatment, there is an obvious risk for misdiagnosis and inappropriate therapy. For instance, the anti-Müllerian hormone (AMH) assay is routinely used to determine the presence of gonads in cats and dogs. [2] [3] [4] [5] Interference in this assay could lead to unnecessary surgery if patients are incorrectly determined to be unneutered. There have been reports of potentially erroneous AMH results in this assay since it was first evaluated in canine samples, 2, 6, 7 and antibody interference has previously been described in people. 8 The presence of discrepant results after various sample treatments is another hallmark of interference. Serial dilutions are sometimes recommended to investigate interference, based on the premise that samples with interfering antibodies will generally display nonlinearity in dilutions. However, the method has been reported to have poor sensitivity with a false-negative rate of 40%, 9 and false-positive results are likely if heterogeneous analytes are being investigated. 10 Blocking of interfering antibodies with nonspecific immunoglobulins (Igs) is another method, but the blocking agents have to be adapted to the specific immunoassay to maximize the chance of success. An alternative approach to tackle immunoassay interference is to deplete the samples of Igs by treating the samples with a precipitant, such as polyethylene glycol (PEG). PEG lowers the solubility of Igs and has been reported to precipitate both serum IgG and IgM efficiently. 11, 12 A sample treatment procedure with PEG is quickly performed, and feasible to implement into normal laboratory routines. The present study aimed to evaluate if antimouse antibodies detected in a species-independent interference assay are a source of erroneous results in the AMH assay and if PEG treatment is a useful tool for detecting antibody interference in a variety of commercial immunoassays used in the veterinary laboratory.
| MATERIAL S AND ME THODS

| Samples
Serum that had tested positive for anti-mouse antibodies in a previous screening study were used, 1 no other inclusion criteria were applied. Serum was frozen and stored at −20°C for up to 18 months until analysis. All samples were thawed at room temperature (RT) and thoroughly vortexed before analysis. Exclusion criteria were clearly visible signs of hemolysis, bilirubinemia, or lipemia.
Control sera were collected from the routine laboratory analysis of progesterone at the University Animal Hospital in Uppsala, Sweden, and from a sampling of staff-owned dogs. Serum was frozen and stored at −20°C for up to 3 months until analysis. All samples were thawed at RT and thoroughly vortexed before analysis. Inclusion criteria for control dogs were a negative anti-mouse antibody test 1 and clinically healthy according to medical records and personal communications with owners. Exclusion criteria were clearly visible signs of hemolysis, bilirubinemia, or lipemia.
| Ethical considerations
The study was approved by the Uppsala Ethical Committee of Animal Experimentation (C 136/13). In accordance with Swedish animal welfare regulations (SJVFS 2015:38), written consent was obtained from all dog owners.
| Immunoassays
For evaluating the effect of anti-mouse antibodies on AMH concentrations, a sandwich ELISA (AMH Gen II, Beckman Coulter, A79765) was used.
For the PEG screening, a panel of immunoassays was selected for inclusion; AMH Gen II, progesterone, canine thyroid-stimulating hormone (TSH), and canine TT 4 (the last three from Siemens Healthcare Diagnostics). The aim was to include immunoassays that are frequently used in the veterinary laboratory, and/or immunoassays where interference could have a high impact on the course of treatment.
All analyses were carried out on an automated chemiluminescent system (Immulite 2000; Siemens Healthineers) except for the AMH assay, which was performed manually. The AMH and canine TSH assays are both noncompetitive immunoassays. The AMH assay is an ELISA with a pair of monoclonal mouse antibodies; one being used for capture and the other for detection. The TSH assay is a chemiluminescent enzyme immunoassay (CLEIA) with a monoclonal mouse antibody on the solid phase and a polyclonal rabbit antibody as the detection antibody.
The progesterone and canine TT 4 CLEIAs are competitive assays where the sample substances compete with enzyme-labeled analytes for binding to a solid phase capture antibody. In the progesterone assay, the solid phase is coated with a polyclonal rabbit antibody and in the canine TT 4 with a murine monoclonal antibody (mAb). All analyses were performed according to the manufacturers' instructions.
| Selection of samples and prioritization of the immunoassay order
To evaluate if anti-mouse antibodies are a source of erroneous results in the AMH assay, neutered dogs were used, seven with anti-mouse antibodies detected using a species-independent assay 1 and seven control dogs. A detectable AMH concentration in neutered dogs with no clinical signs of gonadal tissue present according to patient medical records was considered evidence of interference.
For PEG screening, a general order was established to prioritize when assays were run because of varying sample volumes: (a) AMH;
(b) TT 4 ; (c) TSH; and (d) progesterone. Samples were pretested in the TSH and TT 4 assays to minimize the risk of noninformative results after PEG treatment. Because the TSH results were generally closer to the lower assay detection limit than the TT 4 results, only samples with the 10 highest TSH results were subsequently tested for interference with the PEG method in the TSH assay. The testing of progesterone was limited to intact female dogs. Sample allocation to the different assays is summarized ( Table 1 ). For an overview of all experiments and preparatory steps, see the attached flow chart (Figure 1 ).
| Reduction of interference
Two methods were used to reduce interference; blocking with mouse IgG and PEG precipitation.
Blocking with nonimmune mouse IgG was used for neutered dogs with detectable AMH concentrations. Heat-aggregated 13 In the screening experiment, PEG precipitation was performed by mixing one volume of serum sample with one volume of 24% PEG-6000 (KEBO Lab, Stockholm, Sweden) reconstituted in 0.01 mol/L PBS, pH 7.4 (Sigma Aldrich). The mixture was vortexed and incubated at 4°C for 30 minutes, followed by centrifugation for 5 minutes at 9600g in a Heraeus Fresco 17/21 microcentrifuge (Thermo Fisher, Hemel Hempstead, Hertfordshire, UK). Supernatants were assayed or dispatched immediately to the analyzing laboratory together with the untreated samples, and a 1:2 dilution factor was applied for PEG-treated samples. This treatment was performed on all samples.
When the results from samples treated with PEG and native samples differed by more than four standard deviations (SDs) of the intra-assay coefficient of variation (CV) ( Table 2) , the result was considered to be discrepant. This equals a 99.99% prediction interval for the difference.
| Statistical analysis
In the screening experiment with PEG, differences between two proportions were tested using a two-sample test for equality of proportions with continuity correction. For comparisons involving more than two proportions, a generalized linear model was fitted, and a Chi-square test was then performed for H 0 :p1 = p2 = p3, and so on. 
| RE SULTS
| Samples with anti-mouse antibodies
Twenty-nine samples from 28 dogs positive for anti-mouse antibodies were analyzed in at least one of the immunoassays. When submitting two samples from the same dog, 3 days elapsed between the samplings. The median age of the dogs with anti-mouse antibodies was 7 years, IQR 3.75-9 years. There were 11 intact males, 3 neutered males, 10
intact females, and 4 neutered females of 24 different breeds. 
| Control samples
| Effect of anti-mouse antibodies on the result of the AMH assay
Serum from none of the seven neutered control dogs, but serum from two of seven neutered dogs with anti-mouse antibodies yielded detectable AMH concentrations. These two dogs also had the strongest anti-mouse reactivity of the seven neutered dogs when previously screened for interference. Heat-aggregated MAK33 (0.5 mg/mL) decreased the result by 54% (to 2.64 pmol/L) and 0.5 mg/mL I5381 decreased the adult by 35% (to 3.71 pmol/L). The AMH concentrations were below the detection limit when the serum was treated with PEG.
| Assay screening with PEG
The effects of the PEG treatments are summarized in Table 3 . In total, 127 paired analyses were performed, of which 100 (79%) returned informative results.
Fifteen paired analyses (native vs PEG-treated sera) were below the lower detection limit before and after PEG treatment. Three paired analyses were above the upper detection limit before PEG treatment. Nine paired analyses carried out on the Immulite platform returned the error code "NA" after the PEG treatment. Analyses that were not within the assay range before PEG treatment or that returned an error code after PEG treatment were not included in the analyses. When the post-PEG result was below the assay range, the lowest value was divided by two for statistical calculations.
The probability of getting a discrepant result after PEG treatment differed significantly depending on whether AMH, TSH, TT 4 , or progesterone was analyzed. This was true for samples with antimouse IgG, without anti-mouse IgG, and for all samples (P < 0.001 in all three cases). The presence or absence of anti-mouse antibodies did not influence the probability of getting a discrepant result for any of the assays, except the canine TT 4 assay (P = 0.04).
Five of the 29 patient samples (17%) with anti-mouse antibodies did not have discrepant results in any of the immunoassays.
Conversely, discrepant results were found in at least one of the immunoassays for all 25 serum samples without anti-mouse antibodies.
For assay-specific effects of PEG on samples with anti-mouse antibodies and controls (See Figures 3-6 ).
| D ISCUSS I ON
The present study evaluated if anti-mouse antibodies, detected in a species-independent immunoassay, were a source of erroneous the frequency of interference to 0.03%-4%. [21] [22] [23] [24] Blocking with two types of mouse IgG was used to reduce the effect of interference. Blocking with 0.5 mg/mL purified mouse polyclonal IgG had little to no effect, but 0.5 mg/mL heat-aggregated MAK33 decreased the AMH concentrations by 22% for serum 1 and 54% for serum 2. Increasing the MAK33 concentration to 1.0 mg/mL decreased the AMH concentrations by 57% for serum 1, and normalized the result from 5.71 to < 0.714 pmol/L in serum 2. Although the mechanism is not fully understood, aggregated antibodies have previously been shown to be superior blockers compared with native IgG. 21 In the same study, it was also shown that AMH concentrations could also be caused by bilateral cryptorchidism, but the explicit mention that patient 1 was neutered ruled out this possibility without reasonable doubt, and it would be difficult to explain the effects after adding MAK33 for either patient in the absence of interfering antibodies. After PEG treatments, AMH concentrations in both sera with erroneous results were below the detection limit, but when used for screening, the proportion of discrepant results did not differ between samples with and without anti-mouse antibodies for any of the immunoassays studied, and a very high overall incidence of discrepant results for healthy controls (73%) was observed. This incidence is unrealistically high. For samples containing anti-mouse antibodies, a 57% incidence of interference might not be out of the question, but the incidence was even higher for samples that did not contain any detectable anti-mouse antibodies. It thus follows that the PEG treatment is responsible for the discrepant results, but in most cases, this is unlikely to be due discrepant results obtained with the PEG method is a significant coprecipitation of the analyte with the Igs. A 40% loss of TSH to PEG precipitation has been reported for human samples, but the same study also reported stable values for thyroxine (TT 4 ). 26 This is in contrast to our findings, where 38% of both TSH and TT 4 were lost in healthy controls. There was also a major apparent co-precipitation of AMH (68% for controls). The progesterone assay seemed to be less affected by co-precipitation, as there was a median increase of 1% in progesterone concentrations for the controls, and only 6% of the analyses yielded discrepant results. Further progesterone assay interference studies could be warranted if the exact concentrations are used to determine the optimal time for mating. Before investigating interference with PEG, laboratories should perform in-house tests for specific analytes on control sera to figure out how big a difference is normally expected after PEG treatment.
An extensive evaluation of methods for removal of heterophilic antibodies in canine plasma was performed by Solter et al. 25 Although the favored protocol was relatively lengthy and involved reagents that may not be standard in laboratories, the preliminary results were encouraging. The methods attempted by the Solter group could be preferable to those attempted by our group in the present study, especially if the method is only to be performed in a few selected cases. We also saw promising results when treating sera that had erroneous AMH results with heat-aggregated IgG.
However, this method has to be evaluated more thoroughly before it can be recommended to be used for dog samples. This method is also less convenient to implement in practice, because immunoassays use a variety of different antibodies, and the blocking agent is most effective when it is as similar as possible to the tracer antibody. 27 The fact that antibody interference occurs despite the fact that most (if not all) commercial immunoassay kits are equipped with neutralizing buffers suggests that certain interferences are quite difficult to block with Ig. Blocking solutions tailored to the particular assay are likely to be superior to commercial heterophilic blocking reagents (HBR), which contain multispecies Igs that by chance could be able to bind some interfering substances. 8, 28 Furthermore, the addition of IgG is not likely to be effective against interfering antibodies that bind the variable region of the assay antibodies, such as anti-idiotypic antibodies, nor against auto-analyte antibodies.
Although PEG treatment was not useful in detecting canine antibody interference, interference caused by anti-mouse antibodies in the TSH, TT 4 , and progesterone assays cannot be excluded.
Theoretically, the interference assay is expected to predict interference more accurately for the AMH assay than for any of the other tested assays, because they are both noncompetitive and based on Interfering antibodies that bind the constant region of the assay antibodies can react with a multitude of species, including mouse, rabbit, horse, sheep, and bovine IgG, 29, 30 but with varying and often low affinities, which reduces the likelihood of interference. The progesterone and TT 4 assays use a competitive format, which is less susceptible to interference than the noncompetitive format, 31 unless the antibodies are of high affinity. 32 High-affinity antibodies can be acquired from mAb therapy, but mAb drugs for veterinary use are not available in Sweden.
When immunoassay interference is discussed, it is often presumed that measurements are falsely increased (positive interference). However, negative antibody interference is also possible, will produce less signal in the presence of anti-mouse antibodies, but because of the inverse relationship between signal and concentration in the competitive format, the reported concentrations will be increased.
Interference can also be caused by cross-reactivity due to structural similarities between the analyte and related molecules. Crossreactivity is mostly seen in single antibody-assays. Noncompetitive assays that require simultaneous binding of an analyte to two antibodies (such as the AMH assay) have a much higher analytical specificity and are less susceptible to crossreactivity. 31 The manufacturer states that the AMH assay does not detect human inhibin A, activin the concentrations would not be expected to be depressed by the addition of MAK33. Although not definitively ruled out, cross-reactivity is therefore considered to be a much less likely source of interference in the AMH assay.
A limitation of this study is that the addition of PEG entails the risk of introducing dilution effects and volume inaccuracies, which could lead to discrepancies. However, these problems are inherent to this method and to alternative methods such as blocking with the addition of nonimmune antibodies and would still be encountered if the procedure was implemented in a laboratory protocol.
For a laboratory aiming to take proactive measures against antibody interference, it would be favorable that the same protocol is used to identify interference from a variety of antibodies in a variety of immunoassays. According to our results, PEG treatment of canine samples does not seem to provide such a solution. However, it could be a viable option for identifying interference in cases where the analyte is not affected by co-precipitation.
| CON CLUS ION
Anti-mouse antibodies in dogs are a source of erroneous AMH results. Veterinary clinicians and technicians need to be aware of the risk of immunoassay interference from endogenous antibodies. The PEG method yielded an unrealistically high rate of interference for all examined assays, probably due to co-precipitation of the analyte.
